title: [The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].
abstract: BACKGROUND
  The Sickle Cell Disease (SCD) is a serious illness considering its complications. For the children seriously affected, three therapeutic options are currently validated: transfusion therapy, hydroxyurea and bone-marrow transplantation.
  
  
  OBJECTIVE
  To see the contribution of hydroxyurea therapy on severe forms of SCD in affected Tunisian children.
  
  
  METHODS
  This investigative study lasted over 6 years and 9 months, (September 2000-May 2007), enrolling 47 patients including 27 homozygous SCD and 20 double heterozygote SCD-S/beta thalassemia. The median age was 12 years and a half. The average dosage were 20mg/kg/d (14-30 mg/kg/d). The average duration of treatment was 52 months (18-81 months).
  
  
  RESULTS
  The main indication for hydroxyurea treatment was prevention of recurrence of an acute chest syndrome in seven cases; episodic vaso-occlusive crises exceeding three events per year in 38 cases and prevention of deterioration of cerebral vascular accident in two cases. We observed a fast and sustained improvement of the clinical expression of the disease with a significant decrease of the number of days of hospitalization per patient and per annum from 29.3 d (10-84 d) to 3.2 d/(p<0.01). Treatment was well tolerated. We observed a significant increase of haemoglobin fetus (HbF) rates from 3 to 30% (p<0.01), hemoglobin from 7.8 to 9.6g/dl (p<0.05), average blood cells volume from 79.1 to 100.3 fl (p<0.05) and a significant fall of the white blood cells rates from 14,914 to 8464 per millimetre cube (p<0.05), polynuclear neutrophils from 6799 to 3486 per millimetre cube (p<0.05) and platelets from 508,666 to 293,500 per millimetre cube (p<0.05).
  
  
  CONCLUSIONS
  Hydroxyurea represents a privileged choice of treatment in the severe forms of SCD in children, for homozygous SCD-SS as well as for double heterozygote SCD-S/beta thalassemia. Used carefully, with frequent monitoring, it appeared as a safe treatment in short and medium term, but studies of long-term tolerance should be undertaken.
authors.affiliation: Centre national de greffe de moelle osseuse de Tunis, hôpital de-Jour, 2, rue Djebel-Lakhdhar, 1006 Tunis, Tunisie. melloulif@yahoo.fr
authors.forename: F
authors.initials: F
authors.lastname: Mellouli
authors.forename: M
authors.initials: M
authors.lastname: Bejaoui
mesh_terms: D000755:Anemia, Sickle Cell / Q000188:drug therapy*; D002648:Child; D006579:Heterozygote; D006720:Homozygote; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007902:Length of Stay; D011446:Prospective Studies; D013789:Thalassemia / Q000145:classification / Q000188:drug therapy* / Q000235:genetics; D014416:Tunisia
chemical_list: D006918:Hydroxyurea